Search

Displaying results 2541 - 2550 of 10000 in total
  1. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]

    Synonyms: -CHAIN, (231->224'), (234->227')-BIS(DISULFIDE), IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL
  2. Drug

    Chlorobutanol

    go.drugbank.com/drugs/DB11386
    ApprovedVet approvedWithdrawn

    As a long-term stabilizer of multi-ingredient preparations, chlorobutanol is normally used at a concentration of 0.5%. At this concentration, it also conserves its antimicrobial activity. … Due to the long terminal half-life of 37 days, the use of chlorobutanol as a sedative is limited because of the considerable accumulation which will occur following multiple dosing [A32743].

    Mixtures: DİŞİNOL 2 G + 0,5 G + 3,5 G/10 ML ÇÖZELTİ, NOSTIL 75 MG/60MG/35MG BURUN SPREYİ, ÇÖZELTİ, 15 ML
  3. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  4. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. … Two years later, the research group isolated a compound structurally similar to hydroxymethylglutarate (HMG) that inhibited the incorporation of acetate.

  5. Drug

    Sulfadoxine

    go.drugbank.com/drugs/DB01299
    ApprovedInvestigationalWithdrawn

    A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

    Mixtures: SULFADOXINA 500 MG + PIRIMETAMINA 25 MG TABLETAS
  6. Drug

    Levorphanol

    go.drugbank.com/drugs/DB00854
    Approved

    It is nearly as effective orally as by injection.

  7. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.

    Synonyms: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1
  8. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma … [L46287] It was fully approved by the EMA in May 2023.[L46596]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers
  9. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    The patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly. … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289].

    Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists
  10. Drug

    Cinaciguat

    go.drugbank.com/drugs/DB16126
    Investigational

    Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients